BioPlus Acquisition, Avertix agree to terminate proposed business combination

Avertix Medical and BIOS Acquisition Corporation announced that the two companies have mutually agreed to terminate their proposed business combination. “While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not conducive to completing the transaction on terms acceptable to both BIOS and Avertix stakeholders,” said Tim Moran, CEO of Avertix. “We remain steadfast in our commitment to advancing cardiac care and will continue business as usual, focusing on our core mission of empowering providers with Guardian, the world’s first and only heart attack warning system approved by the FDA. We will likewise continue to monitor the financial markets for opportunities to access additional capital to fund our accelerating growth.”